Gastrointestinal Stromal Tumor Gist Market

DelveInsight's "Gastrointestinal Stromal Tumor (GIST) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Gastrointestinal Stromal Tumor (GIST), historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor (GIST) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gastrointestinal Stromal Tumor (GIST) market report provides current treatment practices, emerging drugs, Gastrointestinal Stromal Tumor (GIST) market share of the individual therapies, current and forecasted Gastrointestinal Stromal Tumor (GIST) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Gastrointestinal Stromal Tumor (GIST) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Gastrointestinal Stromal Tumor (GIST) Disease Understanding and Treatment Algorithm

The DelveInsight Gastrointestinal Stromal Tumor (GIST) market report gives a thorough understanding of the Gastrointestinal Stromal Tumor (GIST) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 


Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Gastrointestinal Stromal Tumor (GIST). 


Treatment 

It covers the details of conventional and current medical therapies available in the Gastrointestinal Stromal Tumor (GIST) market for the treatment of the condition. It also provides Gastrointestinal Stromal Tumor (GIST) treatment algorithms and guidelines in the United States, Europe, and Japan. 


Gastrointestinal Stromal Tumor (GIST) Epidemiology  

The Gastrointestinal Stromal Tumor (GIST) epidemiology division provide insights about historical and current Gastrointestinal Stromal Tumor (GIST) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Gastrointestinal Stromal Tumor (GIST) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 


Country Wise- Gastrointestinal Stromal Tumor (GIST) Epidemiology 

The epidemiology segment also provides the Gastrointestinal Stromal Tumor (GIST) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


Gastrointestinal Stromal Tumor (GIST) Drug Chapters

Drug chapter segment of the Gastrointestinal Stromal Tumor (GIST) report encloses the detailed analysis of Gastrointestinal Stromal Tumor (GIST) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Gastrointestinal Stromal Tumor (GIST) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs 

The report provides the details of the marketed product available for Gastrointestinal Stromal Tumor (GIST) treatment. 


Gastrointestinal Stromal Tumor (GIST) Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Gastrointestinal Stromal Tumor (GIST) treatment. 


Gastrointestinal Stromal Tumor (GIST) Market Outlook

The Gastrointestinal Stromal Tumor (GIST) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Gastrointestinal Stromal Tumor (GIST) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Gastrointestinal Stromal Tumor (GIST) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Gastrointestinal Stromal Tumor (GIST) market in 7MM is expected to change in the study period 2017-2030.


Key Findings

This section includes a glimpse of the Gastrointestinal Stromal Tumor (GIST) market in 7MM.


The United States Market Outlook

This section provides the total Gastrointestinal Stromal Tumor (GIST) market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Gastrointestinal Stromal Tumor (GIST) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Gastrointestinal Stromal Tumor (GIST) market size and market size by therapies in Japan is also mentioned. 


Gastrointestinal Stromal Tumor (GIST) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor (GIST) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Gastrointestinal Stromal Tumor (GIST) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Gastrointestinal Stromal Tumor (GIST) Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Gastrointestinal Stromal Tumor (GIST) key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Gastrointestinal Stromal Tumor (GIST) emerging therapies.


Reimbursement Scenario in Gastrointestinal Stromal Tumor (GIST)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Gastrointestinal Stromal Tumor (GIST) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Gastrointestinal Stromal Tumor (GIST) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Gastrointestinal Stromal Tumor (GIST) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Gastrointestinal Stromal Tumor (GIST), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Gastrointestinal Stromal Tumor (GIST) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Gastrointestinal Stromal Tumor (GIST) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Gastrointestinal Stromal Tumor (GIST) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gastrointestinal Stromal Tumor (GIST) market


Report Highlights

  • In the coming years, Gastrointestinal Stromal Tumor (GIST) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumor (GIST) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Gastrointestinal Stromal Tumor (GIST). Launch of emerging therapies will significantly impact the Gastrointestinal Stromal Tumor (GIST) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Gastrointestinal Stromal Tumor (GIST)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Gastrointestinal Stromal Tumor (GIST) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis
  • Gastrointestinal Stromal Tumor (GIST) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Gastrointestinal Stromal Tumor (GIST) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Gastrointestinal Stromal Tumor (GIST) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Gastrointestinal Stromal Tumor (GIST) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Gastrointestinal Stromal Tumor (GIST) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Gastrointestinal Stromal Tumor (GIST) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Gastrointestinal Stromal Tumor (GIST) market size during the forecast period (2017-2030)?
  • At what CAGR, the Gastrointestinal Stromal Tumor (GIST) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Gastrointestinal Stromal Tumor (GIST) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Gastrointestinal Stromal Tumor (GIST) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Gastrointestinal Stromal Tumor (GIST)?
  • What is the historical Gastrointestinal Stromal Tumor (GIST) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Gastrointestinal Stromal Tumor (GIST) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Gastrointestinal Stromal Tumor (GIST)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Gastrointestinal Stromal Tumor (GIST) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Gastrointestinal Stromal Tumor (GIST) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Gastrointestinal Stromal Tumor (GIST) in the USA, Europe, and Japan?
  • What are the Gastrointestinal Stromal Tumor (GIST) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Gastrointestinal Stromal Tumor (GIST)?
  • How many therapies are developed by each company for Gastrointestinal Stromal Tumor (GIST) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Gastrointestinal Stromal Tumor (GIST) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Gastrointestinal Stromal Tumor (GIST) therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Gastrointestinal Stromal Tumor (GIST) and their status?
  • What are the key designations that have been granted for the emerging therapies for Gastrointestinal Stromal Tumor (GIST)?
  • What are the global historical and forecasted market of Gastrointestinal Stromal Tumor (GIST)?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Gastrointestinal Stromal Tumor (GIST) market
  • To understand the future market competition in the Gastrointestinal Stromal Tumor (GIST) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Gastrointestinal Stromal Tumor (GIST) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Gastrointestinal Stromal Tumor (GIST) market
  • To understand the future market competition in the Gastrointestinal Stromal Tumor (GIST) market

"

1. Key Insights

2. Executive Summary of Gastrointestinal Stromal Tumor (GIST)

3. Competitive Intelligence Analysis for Gastrointestinal Stromal Tumor (GIST)

4. Gastrointestinal Stromal Tumor (GIST): Market Overview at a Glance

4.1. Gastrointestinal Stromal Tumor (GIST) Total Market Share (%) Distribution in 2017

4.2. Gastrointestinal Stromal Tumor (GIST) Total Market Share (%) Distribution in 2030

5. Gastrointestinal Stromal Tumor (GIST): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Gastrointestinal Stromal Tumor (GIST) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Gastrointestinal Stromal Tumor (GIST) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Gastrointestinal Stromal Tumor (GIST) Treatment and Management

8.2. Gastrointestinal Stromal Tumor (GIST) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Gastrointestinal Stromal Tumor (GIST) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Gastrointestinal Stromal Tumor (GIST): Seven Major Market Analysis

13.1. Key Findings

13.2. Gastrointestinal Stromal Tumor (GIST) Market Size in 7MM

13.3. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in the United States

15.1.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in Germany

15.3.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in France

15.4.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in Italy

15.5.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in Spain

15.6.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Gastrointestinal Stromal Tumor (GIST) Total Market Size in the United Kingdom

15.7.2. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Gastrointestinal Stromal Tumor (GIST) Total Market Size in Japan

15.8.3. Gastrointestinal Stromal Tumor (GIST) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Gastrointestinal Stromal Tumor (GIST)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 


Table 1 : 7MM Gastrointestinal Stromal Tumor (GIST) Epidemiology (2017-2030)

Table 2 : 7MM Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Germany (2017-2030)

Table 6 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in France (2017-2030)

Table 8 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in France (2017-2030) 

Table 9 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Italy (2017-2030)

Table 10 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Spain (2017-2030)

Table 12 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in the UK (2017-2030)

Table 14 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15  : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Japan (2017-2030)

Table 16 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Gastrointestinal Stromal Tumor (GIST) Epidemiology (2017-2030)

Figure 2 : 7MM Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in the United States (2017-2030)

Figure 4 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Germany (2017-2030)

Figure 6 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in France (2017-2030)

Figure 8 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Italy (2017-2030)

Figure 10 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Spain (2017-2030)

Figure 12 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in the UK (2017-2030)

Figure 14 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Gastrointestinal Stromal Tumor (GIST) Epidemiology in Japan (2017-2030)

Figure 16 : Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

  • Tags:
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...
  • Gastrointestinal Stromal Tumor (GIS...

Forward to Friend

Need A Quote